SoCal's Atara Biotherapeutics IPO Delayed By New Test Results

Atara Biotherapeutics postponed its expected Thursday IPO after it got new information about one of its drugs, according to a report from Thomson Reuters.

The news agency's International Financing Review cited unnamed sources who said demand has been strong this week for the Brisbane company's offering. But it received new results about an ovarian cancer drug that it will have to disclose before it can go public.

Help employers find you! Check out all the jobs and post your resume.